Anuh PharmaBOM:506260 +1.88%81 Net Margin % is 5.78% as of Mar. 2026, which is 16% below its 10-year median of 6.90. GuruFocus rates BOM:506260 with a GF Score™ of 81/100 and a GF Value™ of ₹105.32 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Anuh Pharma ranks worse than 50.99% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Anuh Pharma's Net Income for the
three
months ended in Mar. 2026 was ₹117 Mil. Anuh Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹2,021 Mil. Therefore, Anuh Pharma's net margin for the quarter that ended in Mar. 2026 was 5.78%.
The historical rank and industry rank for Anuh Pharma's Net Margin % or its related term are showing as below:
BOM:506260'
s Net Margin % Range Over the Past 10 Years
Min: 4.66 Med: 6.9 Max: 9.73
Current: 5.32
BOM:506260's Net Margin % is ranked worse than 50.99% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BOM:506260: 5.32
Anuh Pharma (BOM:506260) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Anuh Pharma Net Margin % Related Terms
Anuh Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Anuh Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anuh Pharma Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Anuh Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anuh Pharma (BOM:506260) has a Net Margin % of 5.78% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Anuh Pharma and its competitors. This is 16% below median its historical median of 6.90. Over the past decade, Anuh Pharma's Net Margin % has ranged from 4.66 to 9.73. According to the industry distribution chart, Anuh Pharma ranks #487 out of 955 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is Anuh Pharma's Net Margin % too high?
Anuh Pharma's current Net Margin % of 5.78% is 16% below median its 10-year median of 6.90. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 9.73. The Drug Manufacturers industry median Net Margin % is 5.69. Anuh Pharma's value of 5.78% is 1.6% above this industry median. Based on the distribution chart, Anuh Pharma ranks #487 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anuh Pharma has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anuh Pharma ranks #487 out of 955 companies for Net Margin %. This places Anuh Pharma in the lower half of its industry. The industry median Net Margin % is 5.69. Anuh Pharma's value of 5.78% is 1.6% above this benchmark. Historically, Anuh Pharma's own Net Margin % has ranged from 4.66 to 9.73 over the past decade. While the company's 10-year median is 6.90 vs. the industry median of 5.69, Anuh Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anuh Pharma's current Net Margin % of 5.78% is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Anuh Pharma and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anuh Pharma's current Net Margin % is 5.78%, which is 16% below median its own 10-year median of 6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (BOM:506260) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹105.32, compared to a current price of ₹81.49 — trading 22.6% below its estimated fair value. The current Net Margin % is 5.78%, which is 16% below median its 10-year median of 6.90 and 1.6% above the Drug Manufacturers industry median of 5.69. Anuh Pharma's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Anuh Pharma (BOM:506260), the current Net Margin % is 5.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anuh Pharma (BOM:506260) Overvalued in 2026?
Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued.
The current stock price of ₹81.49 is trading 22.6% below its estimated GF Value™ of ₹105.32.
GuruFocus considers Anuh Pharma to be Modestly Undervalued.
Key valuation signals for BOM:506260:
Net Margin %: 5.78% (16% below median its 10-year median of 6.90)
GF Value™: ₹105.32 vs. price of ₹81.49 (22.6% below fair value)
Industry Position: 1.6% above the Drug Manufacturers median (#487 of 955)
No single metric tells the full story. See the BOM:506260 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
81GF Score
Get the complete analysis for BOM:506260
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506260 has been successfully added to your 
